share_log

丽珠集团(000513.SZ):前三季度促性激素产品实现收入23.08亿元,增速为5.46%

livzon pharmaceutical group inc. (000513.SZ): In the first three quarters, the revenue of hormone products reached 2.308 billion yuan, with a growth rate of 5.46%.

Gelonghui Finance ·  Oct 31, 2024 16:59

Gelonghui October 31st | Livzon Pharmaceutical Group Inc. (000513.SZ) stated during a specific target survey on October 31, 2024, that in the first three quarters, revenue from sex hormone products reached 2.308 billion yuan, with a growth rate of 5.46%. The key product, Liangbiruilin microspheres, as a hormonal regulatory drug, has high technological barriers and a good competitive landscape, with minimal policy impact. Currently, Liangbiruilin microspheres have passed consistency evaluation, and it is expected to maintain a differentiated competitive advantage in the near future.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment